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MaWe present a case of recurrent isolated cardiac sarcoidosis, 3 years post-heart transplantation. The case highlights
the scarcity of data on the utility of immunosuppression in cardiac sarcoidosis and, in particular, raises questions
about the optimal immunosuppression regimen in transplant recipients. (Level of Difficulty: Advanced.) (J Am Coll
Cardiol Case Rep 2021;3:427–32) © 2021 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).HISTORY OF PRESENTATION
A 43-year-old man presented to the heart transplant
clinic with palpitations, 3 years post-transplantation
for isolated cardiac sarcoidosis. His personal heart
rate monitor had detected intermittent bursts of
tachycardia exceeding 200 beats/min during exercise.
His regular medications included tacrolimus, ever-
olimus, aspirin, trimethoprim-sulfamethoxazole,
cholecalciferol, calcium, magnesium, and pravasta-
tin. Hemodynamic parameters and examination were
unremarkable.EARNING OBJECTIVES
To make a differential diagnosis of recurrent
disease in patients with ventricular arrhyth-
mias post-heart transplantation for cardiac
sarcoidosis.
To understand the complexities of prolonged
corticosteroid use in cardiac sarcoidosis.
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The patient had undergone heart transplantation 3
years earlier for presumed idiopathic dilated cardio-
myopathy with recurrent ventricular tachycardia (VT)
necessitating implantation of a secondary prevention
cardioverter-defibrillator. He had no other significant
medical history and was a nonsmoker with no family
history of cardiomyopathy. Only at the time of his-
tological assessment of the explanted heart was the
cardiomyopathy determined to be secondary to car-
diac sarcoidosis on the basis of the presence of
granulomatous inflammation composed of numerous
tightly packed, small, non-necrotizing granulomas
typical of the disease (Figure 1A). In addition, single
multinucleated giant cells were found within the
myocardium (Figure 1B). Rigorous review of the pa-
tient’s transplantation work-up data, including whole
body computed tomography and subsequent
screening for extracardiac sarcoidosis, revealed no
evidence of other organ involvement.https://doi.org/10.1016/j.jaccas.2020.11.025
. Kevin Shah, MD, served as the Guest Editor for this
es and animal welfare regulations of the authors’






ABBR EV I A T I ON S
AND ACRONYMS
CMR = cardiac magnetic
resonance
SCD = sudden cardiac death
VT = ventricular tachycardia
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428The patient’s early recovery from heart
transplantation was relatively unremarkable.
He was successfully treated with valganci-
clovir for cytomegalovirus reactivation and
had a single episode of grade 2R cellular
rejection requiring a pulse of intravenous
methylprednisolone, followed by a weaningregimen of prednisone. Prednisone was successfully
weaned to cessation by the 18th month following
transplantation, in conjunction with consistently
negative surveillance endomyocardial biopsy results
and the titration of everolimus and tacrolimus. His
smooth recovery enabled him to return to his pre-
morbid penchant for mountain bike racing within a
year of heart transplantation.
DIFFERENTIAL DIAGNOSIS
The differential diagnosis was broad, including elec-
trolyte abnormalities, coronary artery vasculopathyE 1 Histological Assessments
tensive granulomatous inflammation composed of numerous tigh
cation 4) (B) Single multinucleated giant cells (arrow) within m
domyocardial biopsy of the transplanted heart showing scattered
cation 10).or other disease, structural and conduction abnor-
malities, and cardiac rejection, as well as medication
complications.
INVESTIGATIONS
The patient’s electrolyte levels were normal. His
electrocardiogram demonstrated sinus rhythm with
right-axis deviation and a nonspecific intraventric-
ular conduction delay resulting in a QRS complex
duration of 150 ms (Figure 2B). Earlier post-transplant
electrocardiograms had shown sinus rhythm without
evidence of conduction delay or axis shift (Figure 2A);
this change suggested the potential development of
conduction system disease. The echocardiogram
demonstrated normal left ventricular size and func-
tion, despite the presence of a new regional wall
motion abnormality at the basal septum. Coronary
computed tomography angiography was performed
out of concern for coronary artery vasculopathy ortly packed, small, non-necrotizing granulomas (arrows) (original
yocardium of the explanted heart (original magnification 10).
multinucleated giant cells (arrow) within the myocardium (original
FIGURE 2 Electrocardiograms
(A) Electrocardiogram recorded 3 years earlier, in the early post-transplantation period, demonstrating no conduction delay. (B) Electro-
cardiogram on presentation demonstrating nonspecific intraventricular conduction delay with right-axis deviation.
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429other disease and identified mixed plaque in the
proximal left anterior descending artery with 20%
luminal stenosis. A subsequent exercise stress echo-
cardiogram showed no evidence of inducible
ischemia at a high aerobic capacity. Holter monitoring
revealed multiple episodes of symptomatic VT
(Figure 3).
The patient subsequently underwent cardiac
magnetic resonance (CMR), which demonstrated wall
thinning, hypokinesis, and near transmural lategadolinium enhancement of the basal interventric-
ular septum without active myocardial inflammation
or edema, findings suggestive of sarcoidosis
(Figure 4). This diagnosis was then confirmed histo-
logically following examination of endomyocardial
biopsy specimens (Figure 1C) in which scattered
multinucleated giant cells were seen within the
myocardium. Repeat screening for extracardiac
sarcoidosis again demonstrated no other detectable
organ involvement.
FIGURE 3 Telemetry Demonstrating Ventricular Tachycardia
HR ¼ heart rate; VT ¼ ventricular tachycardia.
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430MANAGEMENT
Implantable cardiac resynchronization therapy with a
defibrillator was inserted in response to the patient’s
symptomatic VT, his wide left bundle branch block on
electrocardiogram, the presence of significant burden
of fibrosis on CMR, and the acknowledgment of the
patient’s clinical course before transplantation,
which had resulted in end-stage biventricular heartFIGURE 4 Cardiac Magnetic Resonance
Basal slice from short-axis stack series of late gadolinium
enhancement images (phase-sensitive inversion recovery)
showing near transmural late gadolinium enhancement of the
basal septum (arrow).failure. A steroid bolus of methylprednisolone, 1 g
daily for 3 days, was commenced, followed by a
weaning schedule of prednisone starting at 1 mg/kg in
divided doses, weaned by 5 mg/day until a dose of
20 mg daily was reached, after which the patient had
a more gradual taper down to a maintenance dose of
7.5 mg daily. The patient continues to take predni-
sone, in conjunction with other immunosuppressive
medications. He was discharged home, with ongoing
follow-up in the heart transplant clinic.
DISCUSSION
Sarcoidosis is a relatively rare multisystem disease of
unknown etiology, with estimates of 20% to 30% of
affected patients demonstrating myocardial granu-
lomas at autopsy (1,2). The diagnosis of cardiac
sarcoidosis is important given its pathological
sequelae, including sudden cardiac death (SCD),
ventricular tachyarrhythmias, complete heart block,
and cardiomyopathy (3).
Heart transplantation resulting from cardiac
sarcoidosis is an option for patients with incessant
arrhythmias or refractory end-stage heart failure
despite optimal medical therapies, although data on
outcomes post-transplantation are conflicting (4).
Some data suggest similar or improved outcomes
post-transplantation from cardiac sarcoidosis
compared with other disorders, whereas a retro-
spective review by Akashi et al. (4) showed a trend
toward higher mortality in patients with cardiac
sarcoidosis. Individuals who undergo heart trans-
plantation are pharmacologically immunosuppressed
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431lifelong, regardless of cause. At our institution (St.
Vincent’s Hospital, Sydney, Australia), we endeavor
to wean patients from corticosteroids in line with
endomyocardial biopsy surveillance results because
of the widespread deleterious side effects of this
therapy (5). This transition often involves
commencement of a mammalian target of rapamycin
inhibitor such as everolimus, given its anti-
proliferative effects and protection from coronary
artery vasculopathy (6), in conjunction with myco-
phenolate and tacrolimus.
This is one of few reported cases of recurrent iso-
lated cardiac sarcoidosis in a transplanted heart, and
it raises the question of how to best avoid relapse.
Even in the patients who are not transplant re-
cipients, data are limited and conflicting when
comparing patients with cardiac sarcoidosis who are
treated with immunosuppression with patients with
cardiac sarcoidosis who are not receiving any immu-
nosuppressive agents. In a study by Vignaux et al. (7),
the investigators found that patients who had
received corticosteroids had improved CMR findings
at 12-month follow-up compared with patients who
had not received treatment. Similarly, Osborne et al.
(8) found with, serial positron-emission tomography
imaging, that corticosteroid therapy was associated
with an improvement in left ventricular ejection
fraction in patients with cardiac sarcoidosis who
demonstrated reduction in myocardial inflammation.
It has been suggested that such therapies may be of
particular benefit if they are started before scar for-
mation and irreversible ventricular dysfunction oc-
curs (9). However, we have previously found no
significant difference in the rate of VT or SCD be-
tween patients with CMR detected cardiac sarcoidosis
who are receiving corticosteroid therapy and those
who are not receiving therapy (1). Therefore, despite
some evidence indicating improved cardiac function
and imaging parameters, there is a relative deficiency
of evidence to suggest that continued systemic
corticosteroid use reduces the manifestation and
clinical sequelae of cardiac involvement from
sarcoidosis. Data pertaining to the transplant recip-
ient with sarcoidosis are even more scarce. In a studyby Perkel et al. (10), a few patients with cardiac
sarcoidosis who underwent heart transplantation
were maintained on low-dose corticosteroids, and
none had recurrent disease. These limited data—at
least anecdotally—present a case for continued corti-
costeroid therapy in this subgroup of heart transplant
recipients (10).
FOLLOW-UP
The patient was able to return to normal physical
activities soon, with no further palpitations. He has
had 3 cardiac device checks, demonstrating 4 epi-
sodes of nonsustained VT, but none requiring anti-
tachycardia pacing or implantable cardioverter-
defibrillator therapy. He has continued on low-dose
prednisone, and repeat CMR a year later showed an
appearance similar to that of his previous study. Now
almost 2 years post-presentation, and 5 years post-
initial transplantation, he remains asymptomatic,
with preserved allograft function.
CONCLUSIONS
In this case report, we explore the recurrence of
cardiac sarcoidosis after heart transplantation. The
case was unique by the absence of discernible
extracardiac sarcoidosis. There is a scarcity of evi-
dence on the optimal treatment regimen to avoid
recurrence of cardiac sarcoidosis in heart transplant
recipients. This case raises questions about the po-
tential utility of lifelong low-dose corticosteroids as
part of the immunosuppression regimen in such
patients.
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